Latest News
Charles River Laboratories Acquires UK CRO KWS BioTest
Friday 12 January 2018

12 January 2018 - Massachusetts, US-based pre-clinical and clinical laboratory services provider Charles River Laboratories International, Inc. (NYSE: CRL) has acquired UK-based contract research organisation KWS BioTest, the company said.

KWS BioTest specialises in in vitro and in vivo discovery testing services for immuno-oncology and inflammatory and infectious diseases.

The addition of KWS enhances Charles River's discovery expertise, with complementary offerings that provide our clients with additional tools in the active therapeutic research areas of oncology and immunology.

Charles River said the purchase price was approximately GBP 15m in cash (approximately USD 20m based on current exchange rates), subject to certain post-closing adjustments.

In addition to the initial purchase price, the transaction includes a potential additional payment of up to GBP 3m based on future performance (approximately USD4 m based on current exchange rates).

The transaction is not expected to be material to 2018 GAAP or non-GAAP results from operations.

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts.
Date Published: 12/01/2018
Target: KWS BioTest
Country: UK
Sector: Pharmaceuticals
Type: Corporate acquisition
Status: Closed
Buyer: Charles River Laboratories
Terms of the deal were not disclosed